Exhibit 4.10
DIRECTOR NOMINATION AGREEMENT
THIS DIRECTOR NOMINATION AGREEMENT (this “Agreement”) is made and entered into as of October 8, 2021, by and among LianBio, a Cayman Islands exempted company (the “Company”), Perceptive Life Sciences Master Fund, Ltd., a Cayman Islands exempted company, LEV LB Holdings, LP, a limited partnership formed in the State of Delaware, Perceptive Xontogency Venture Fund, LP, a limited partnership formed in the State of Delaware, and C2 Life Sciences LLC, a New York limited liability company (collectively, “Perceptive”). This Agreement shall become effective (the “Effective Date”) upon the closing of the Company’s proposed initial public offering (the “IPO”) of American depositary shares (“ADS”), representing its ordinary shares, par value $0.0001 per share (the “Ordinary Shares”).
WHEREAS, as of the date hereof, Perceptive beneficially owns a majority of the equity interests in the Company;
WHEREAS, Perceptive and the Company are contemplating causing the Company to effect an IPO;
WHEREAS, Perceptive currently has the authority to appoint a majority of the directors of the Company;
WHEREAS, in consideration of Perceptive agreeing to undertake the IPO, the Company has agreed to permit Perceptive to designate persons for nomination for election to the board of directors of the Company (the “Board”) following the Effective Date on the terms and conditions set forth herein;
NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of the parties to this Agreement agrees as follows:
| 1. | Board Nomination Rights. |
| (a) | From the Effective Date, Perceptive shall have the right, but not the obligation, to nominate to the Board a number of designees equal to at least: (i) 66% of the Total Number of Directors, so long as Perceptive continuously from the time of the IPO Beneficially Owns Ordinary Shares representing at least 75% of the Original Perceptive Owned Shares, (ii) 55% of the Total Number of Directors, in the event that Perceptive continuously from the time of the IPO Beneficially Owns Ordinary Shares representing at least 50% but less than 75% of the Original Perceptive Owned Shares, (iii) 40% of the Total Number of Directors, in the event that Perceptive continuously from the time of the IPO Beneficially Owns Ordinary Shares representing at least 25% but less than 50% of the Original Perceptive Owned Shares, (iv) 25% of the Total Number of Directors, in the event that Perceptive continuously from the time of the IPO Beneficially Owns Shares representing at least 10% but less than 25% of the Original Perceptive Owned Shares and (v) one director, in the event that Perceptive continuously from the time of the IPO Beneficially Owns Ordinary Shares representing at least 5% but less than 10% of the Original Perceptive Owned Shares (such persons, the “Nominees”). For purposes of calculating the number of directors that Perceptive is entitled to designate pursuant to the immediately preceding sentence, any fractional amounts shall automatically be rounded up to the nearest whole number (e.g., 1 1/4 Directors shall equate to 2 Directors) and any such calculations shall be made after taking into account any increase in the Total Number of Directors. For so long as Perceptive continuously from the time of the IPO Beneficially Owns Ordinary Shares representing at least 25% of the Original Perceptive Owned Shares, Perceptive shall have the right to nominate the Chairman of the Board. |
1